Finanzen von Artiva Biotherapeutics Inc (ARTV)ARTVArtiva Biotherapeutics Inc

Evaluating the bottom line, Artiva Biotherapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -36.58%, provide a clear picture of how effectively ARTV converts its operational activities into shareholder value.

In the context of the broader market, ARTV competes directly with industry leaders such as NATR and NAGE. With a market capitalization of $202.16M, it holds a leading position in the sector. When comparing efficiency, ARTV's gross margin of N/A stands against NATR's 72.86% and NAGE's N/A. Such benchmarking helps identify whether Artiva Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

Artiva reported a net loss of $23.5 million for Q1 2026, widening from a loss of $20.3 million in Q1 2025. The company has a gross margin of 0% in recent quarters, indicating challenges in generating revenue.